We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Decreased cardiac mortality with nicorandil in patients with ischemic heart failure.
- Authors
Akiomi Yoshihisa; Yu Sato; Shunsuke Watanabe; Tetsuro Yokokawa; Takamasa Sato; Satoshi Suzuki; Masayoshi Oikawa; Atsushi Kobayashi; Yasuchika Takeishi; Yoshihisa, Akiomi; Sato, Yu; Watanabe, Shunsuke; Yokokawa, Tetsuro; Sato, Takamasa; Suzuki, Satoshi; Oikawa, Masayoshi; Kobayashi, Atsushi; Takeishi, Yasuchika
- Abstract
<bold>Background: </bold>Effective treatments in heart failure (HF) patients with ischemic etiology have not been fully established. Nicorandil, combination of nitrate component and sarcolemmal adenosine triphosphate-sensitive potassium channel opener, is a potent vasodilator of coronary and peripheral vessels and has been used as an antianginal agent. Therefore, we examined impacts of nicorandil on cardiac mortality in ischemic HF patients.<bold>Methods: </bold>Consecutive 334 HF patients with ischemic etiology were retrospectively registered and divided into 2 groups based on oral administration of nicorandil: nicorandil group (n = 116) and non-nicorandil group (n = 218). We retrospectively examined cardiac mortality.<bold>Results: </bold>In the Kaplan-Meier analysis (mean follow-up period 963 days), cardiac mortality was significantly lower in the nicorandil group than in the non-nicorandil group (11.2% vs. 19.7%, P = 0.032). In the Cox proportional hazard analysis, usage of nicorandil was a suppressor of cardiac mortality (hazard ratio 0.512, 95% confidence interval 0.275-0.953, P = 0.035), and this result was consistent in several subgroup analyses, such as left ventricular ejection fraction, percutaneous coronary intervention, coronary artery bypass graft, diabetes, β-blockers, and statins.<bold>Conclusion: </bold>Nicorandil is potentially effective for reducing mortality in patients with ischemic heart failure.<bold>Trial Registration: </bold>This was a retrospective study.
- Subjects
CORONARY disease; CORONARY heart disease treatment; DRUG efficacy; ADENOSINE triphosphate analysis; NICORANDIL; PATIENTS; CORONARY heart disease complications; HEART failure; MYOCARDIAL depressants; NITRATES; TIME; TREATMENT effectiveness; VASODILATORS; PROPORTIONAL hazards models; RETROSPECTIVE studies; KAPLAN-Meier estimator; THERAPEUTICS
- Publication
BMC Cardiovascular Disorders, 2017, Vol 17, p1
- ISSN
1471-2261
- Publication type
journal article
- DOI
10.1186/s12872-017-0577-3